Nomogram to assess the survival benefit of new salvage agents for metastatic urothelial carcinoma in the era of immunotherapy

INTRODUCTION: Optimal endpoints in phase II trials evaluating salvage therapy for metastatic urothelial carcinoma (mUC) are necessary to identify promising drugs, particularly immunotherapeutics, where response and progression-free survival may be unreliable. We developed a nomogram using data from...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Genitourin Cancer
Main Authors: Sonpavde, Guru, Pond, Gregory Russell, Rosenberg, Jonathan E., Choueiri, Toni K., Bellmunt, Joaquim, Regazzi, Ashley Marie, Mullane, Stephanie A., Necchi, Andrea, Raggi, Daniele, Lee, Jae-Lyun, Lee, Soonil, Simpson, Joe, Derleth, Christina Louise, Lin, Shih-Wen, Bajorin, Dean F.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697267/
https://ncbi.nlm.nih.gov/pubmed/29706503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.03.016
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares